BONESUPPORT Q1: A quarter cementing our thesis
Research Note
2021-05-06
13:56
Redeye’s optimistic view on the BONESUPPORT case remains following today’s report despite a slowdown in sales growth. We expect orthopaedic surgeries to accelerate significantly during H2, which, together with several exciting near-term catalysts, should fuel both its share price and revenue growth.
OB
Oscar Bergman
Disclosures and disclaimers